Academe Learn
CBME Curriculum Preview

Page 15 of 15

IM8.{1-8,10-19} | Hypertension — PBL Case

CLINICAL SETTING

Dr Kavitha is the medical registrar on call in the General Medicine ward of a tertiary teaching hospital in Chennai. A 52-year-old government clerk, Mr Mohan Kumar, is brought to the emergency department by his wife at 11 pm. He has had a severe throbbing headache since morning, worse in the last two hours, and his wife noticed that his speech seemed 'not right' for about 20 minutes before they left home — she thinks he was mumbling and confused, though he seems clearer now. He has no chest pain or dyspnoea. He is a known hypertensive for 8 years, on one tablet (he thinks 'the white one'), but admits he ran out of his medications 10 days ago. He is a non-smoker, drinks alcohol occasionally, and works long hours. He is vegetarian. His wife adds: 'He has never bothered about his blood pressure — he always says he has no symptoms.' On initial assessment, BP is 204/128 mmHg (right arm, sitting), pulse 90/min regular, RR 18/min, SpO2 98% on air. He appears alert and orientated now. The junior doctor accompanying Dr Kavitha opens the case sheet and looks at the students: 'What do we need to find out first?'

Trigger 1: Emergency Department — First Assessment

Dr Kavitha performs a rapid examination. Repeat BP: right arm 206/130, left arm 200/126 (both elevated, difference <10 mmHg — aortic dissection less likely). Pulse 88/min, regular. JVP not elevated. Cardiac auscultation: an S4 gallop at the apex, no murmurs. Respiratory exam normal — no crackles. Neurological: GCS 15/15, no focal deficit now; pupils equal and reactive. She then performs fundoscopy: bilateral flame-shaped haemorrhages and cotton wool spots are visible; she looks for papilloedema but is unsure — the disc margins are blurred bilaterally. She sends bloods urgently: creatinine 2.8 mg/dL (his last creatinine 6 months ago was 1.1 mg/dL), potassium 4.0 mEq/L, sodium 142 mEq/L, haemoglobin 11.2 g/dL with fragmented cells on peripheral smear, platelet count 118,000/mm3. Urine dipstick: protein 3+, blood 2+. Non-contrast CT head is performed: no haemorrhage, no space-occupying lesion. Dr Kavitha turns to the students: 'This is not what I initially expected. Let me tell you what I think is happening, and you tell me what confirms it.'

DISCUSSION POINTS

  • The combination of severely elevated BP, bilateral flame haemorrhages and probable papilloedema, acute rise in creatinine, microangiopathic haemolytic anaemia (fragmented cells), thrombocytopaenia, and heavy proteinuria — what syndrome does this constellation represent, and how does it differ from a simple hypertensive urgency?
  • Mr Mohan had a transient 20-minute episode of slurred speech and confusion that resolved fully. How does this change the neurological assessment, and what diagnosis should be considered alongside the hypertensive emergency?
  • What is the immediate management priority — lowering BP rapidly to normal, targeting a 20-25% MAP reduction, or awaiting further investigations before treating? Justify your answer using pathophysiology.
Click to reveal Trigger 2: ICU — Hour 6: Controlled Treatment and Unexpected Biochemistry (discuss previous trigger first!)

Trigger 2: ICU — Hour 6: Controlled Treatment and Unexpected Biochemistry

Mr Mohan is admitted to the ICU. IV labetalol infusion is started. Over 90 minutes, his BP is reduced to 174/106 mmHg (approximately 20% MAP reduction from 154 mmHg to 129 mmHg). He is now alert, headache has partially resolved, and there are no new neurological symptoms. His creatinine at 6 hours is 3.1 mg/dL — slightly higher than on admission. The team reviews the potassium: it is now 5.2 mEq/L. The intern expresses concern that the creatinine is rising despite BP control and asks whether the ACE inhibitor should be started now to 'protect the kidneys'. Dr Kavitha disagrees. Meanwhile, the nephrology registrar suggests checking an aldosterone-to-renin ratio once BP is stabilised, noting that the hypokalaemia seen on an outpatient visit 2 years ago (potassium 3.4, unreported to the patient) may be relevant. She also notes that Mr Mohan's HTN was diagnosed at age 44 — younger than typical essential HTN. A family history review reveals no hypertension in parents or siblings. Dr Kavitha tells the students: 'We have treated the crisis. Now we need to ask — why did he have this crisis in the first place?'

DISCUSSION POINTS

  • The creatinine has risen slightly further after BP reduction. Is this a sign of ACE inhibitor nephrotoxicity, therapeutic success, or ongoing malignant hypertension injury? What is the expected renal response to controlled BP reduction in malignant hypertension?
  • The team is debating adding an ACE inhibitor acutely (within the first 6 hours of hypertensive emergency). What are the specific risks of ACE inhibition in this patient at this moment, and when — if ever — would you introduce RAAS blockade in acute malignant HTN with AKI?
  • Mr Mohan has onset of hypertension at age 44, no family history, and a previous unexplained hypokalaemia. Construct a differential diagnosis of secondary hypertension and rank the most likely cause based on available evidence.
Click to reveal Trigger 3: Day 4 — Stabilised, Secondary Workup Underway (discuss previous trigger first!)

Trigger 3: Day 4 — Stabilised, Secondary Workup Underway

By day 4, Mr Mohan's BP is 148/92 mmHg on oral labetalol 200 mg twice daily and oral amlodipine 5 mg. His creatinine has improved to 2.1 mg/dL. His aldosterone-to-renin ratio returns: aldosterone 32 ng/dL, plasma renin activity 0.4 ng/mL/hr — ARR = 80 (significantly elevated; cut-off >30 is positive). He is sent for adrenal CT: a 2.1 cm hypodense right adrenal adenoma is found. The diagnosis is confirmed as primary hyperaldosteronism with an adrenal adenoma. Dr Kavitha explains to the students: 'His hypertension was never primary — it was driven by this adenoma for years. Every year he did not know about this, his kidneys were silently damaged. His malignant hypertension crisis was the end result of 8 years of untreated, undiagnosed secondary hypertension.' She asks: 'What should have been done differently at every step — at diagnosis, during follow-up, and at this admission?'

DISCUSSION POINTS

  • Primary hyperaldosteronism was the likely driver of his hypertension for at least 8 years. What clinical and biochemical clues (past history of hypokalaemia, young onset, no family history, poor BP control) should have prompted earlier secondary cause screening, and at what stage of the management algorithm is ARR indicated?
  • Spironolactone is recommended as the medical treatment for bilateral adrenal hyperplasia. For a unilateral adenoma (Conn adenoma) confirmed on adrenal CT, what is the preferred treatment approach, and how do you determine whether the adenoma is the functional source before surgical referral?
  • Over the next 2 years, what is the expected trajectory of Mr Mohan's renal function, BP control, and cardiovascular risk if: (a) the adenoma is surgically removed, versus (b) he continues on medical therapy only with spironolactone?
Click to reveal Trigger 4: Discharge and Counselling — Navigating Non-Adherence and Long-Term Risk (discuss previous trigger first!)

Trigger 4: Discharge and Counselling — Navigating Non-Adherence and Long-Term Risk

Mr Mohan is planned for right adrenalectomy in 6 weeks after optimisation. He will be discharged on amlodipine 5 mg and spironolactone 25 mg (for potassium balance pre-operatively). Before discharge, a social worker notes that Mr Mohan earns a modest salary and has to travel 45 minutes by bus to the hospital. He has two children in school. He admits that he stopped his medication because it was 'expensive and I thought I was fine — I had no pain.' He adds: 'The doctor never told me blood pressure was dangerous if I felt okay. I thought it was just a number.' His wife is worried about his work capacity after discharge. Dr Kavitha sits with the family for 20 minutes. She asks the final-year student to lead the counselling session. The student must address: why adherence matters even when there are no symptoms; specific lifestyle changes that lower BP and are feasible for this patient; and what the impact of uncontrolled hypertension has been and could be on his quality of life, work, and family.

DISCUSSION POINTS

  • Mr Mohan's non-adherence was partly driven by cost, lack of symptoms, and poor patient education. Design a structured patient education session for a hypertensive patient who believes that 'no symptoms means no problem'. What communication strategies are most effective for asymptomatic chronic disease?
  • Mr Mohan needs to understand the concept of silent target organ damage. Using the findings in his case — LVH (S4 gallop), CKD, malignant retinopathy — explain in plain language (not medical jargon) what has already happened to his body, and what this means for his future if BP is well controlled versus if it is not.
  • He is being discharged on two medications. Identify three practical adherence barriers in his specific social context (cost, travel, asymptomatic disease) and for each barrier describe one evidence-based or feasible intervention that his treating team can implement.

Group Task Assignments

  • Construct the complete diagnostic and management algorithm for a patient with hypertension onset before age 50, no family history, and a past episode of unexplained hypokalaemia. Define the step-by-step secondary cause workup with specific investigations, their cut-offs, and confirmation tests.
  • Role-play the counselling session for Mr Mohan on day of discharge. One student plays the patient (with his specific barriers — cost, asymptomatic disease, work pressure). Another student plays the doctor. Record and debrief on: how the doctor explained target organ damage in lay language, how adherence barriers were addressed, and what follow-up plan was communicated.
  • Prepare a one-page 'Hypertensive Emergency Protocol' for a district hospital with limited ICU resources. Address: identification criteria, first-line IV drug (and preparation), MAP reduction target and timeframe, neurological monitoring, and criteria for higher-centre transfer.
  • Debate the proposition: 'Screening the aldosterone-to-renin ratio in ALL newly diagnosed hypertensive patients under 60 years of age, regardless of potassium level, would detect more curable secondary hypertension than the current selective-screening approach.' What are the arguments for and against? What is the cost-effectiveness argument in the Indian public health context?

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [IM8.5] What is the precise clinical definition of hypertensive emergency versus urgency, and what pathophysiological mechanism produces malignant hypertension with microangiopathic injury?
  2. [IM8.6] What is primary hyperaldosteronism, what are the clinical and biochemical clues that should prompt screening, and what is the aldosterone-to-renin ratio test pathway including cut-offs?
  3. [IM8.7] What is the Keith-Wagener classification of hypertensive retinopathy, what does each grade signify, and at what grade does hypertension become a medical emergency?
  4. [IM8.14] What IV antihypertensive agents are available for hypertensive emergency management, what are the drug-specific indications and contraindications, and what is the evidence-based MAP reduction target in the first hour?
  5. [IM8.17] What communication strategies are effective for patients with asymptomatic chronic disease who believe 'no symptoms means no problem', and how should adherence barriers be systematically identified and addressed?